R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed... Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.
- Mechanism
- Curator reviewed
Pharmacologically active on Cyclin-dependent kinase 5, Cyclin-dependent kinase 2, and Cyclin-dependent kinase 7
- Primary indication
- Investigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified).Curator reviewed
- Formula / weight
- C19H26N6O · 354.4493 g/mol (avg)
- Also known as
- R-roscovitine
- Code names
- AL-39256 · CYC-202 · NSC-701554
Resolves to
BTIHMVBBUGXLCJ-OAHLLOKOSA-NSMILESCC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1What you can answer from here — as of June 15, 2026
Which drugs share a target with Seliciclib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account